Free tool
FAERS Monitor: Spevigo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761244 or its brand name (Spevigo, Spesolimab-Sbzo). Reports on generic versions are filed under their own applications.
Reports
403
Serious
213
53% of reports
Hospitalization
88
Death reported
28
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- generalised pustular psoriasis82
- drug ineffective54
- off label use26
- pruritus22
- rash20
- fatigue19
- pustular psoriasis19
- psoriasis16
- pustule15
- maternal exposure during pregnancy14
- asthenia13
- pyrexia13
- diarrhoea12
- therapeutic product effect incomplete12
- urinary tract infection12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 13 |
| 2023 | 64 |
| 2024 | 98 |
| 2025 | 115 |
| 2026 | 113 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,756 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| generalised pustular psoriasisSignal | 82 | 20595.6 | 16263.0 | 1,196,479 |
| pustuleSignal | 15 | 332.5 | 202.0 | 4,602 |
| pustular psoriasisSignal | 19 | 290.3 | 186.9 | 5,165 |
| therapeutic product effect incompleteSignal | 12 | 8.8 | 5.0 | 76 |
| maternal exposure during pregnancySignal | 14 | 8.2 | 4.9 | 82 |
| psoriasisSignal | 16 | 6.4 | 4.0 | 68 |
| urinary tract infectionSignal | 12 | 3.7 | 2.1 | 21 |
| pruritusSignal | 22 | 3.0 | 2.0 | 28 |
| rashSignal | 20 | 2.4 | 1.6 | 15 |
| drug ineffectiveSignal | 54 | 2.1 | 1.7 | 34 |
| pyrexia | 13 | 2.0 | 1.1 | 5 |
| asthenia | 13 | 1.8 | 1.1 | 4 |
| off label use | 26 | 1.5 | 1.1 | 5 |
| fatigue | 19 | 1.3 | 0.8 | 1 |
| diarrhoea | 12 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.